SHAREHOLDERS’ EQUITY (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands										1 Months Ended				3 Months Ended	12 Months Ended
	Oct. 08, 2025	Apr. 01, 2025	Jan. 16, 2025	Jan. 14, 2025	Nov. 12, 2024	Oct. 01, 2024	Sep. 23, 2024	Sep. 17, 2024	Sep. 16, 2024	Jul. 31, 2025	Jun. 30, 2025	May 31, 2025	Sep. 30, 2024	Dec. 31, 2024	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Jul. 31, 2023	May 10, 2023	Dec. 31, 2022	Dec. 31, 2021
Subsidiary, Sale of Stock [Line Items]
Shares authorized																			120,000,000
Common stock, shares issued														100,000,000	100,000,000	100,000,000			100,000,000
Common stock, par value														$ 0.001	$ 0.001	$ 0.001			$ 0.001
Preferred stock, shares authorized														20,000,000	20,000,000	20,000,000			20,000,000
Preferred stock par value														$ 0.001	$ 0.001	$ 0.001			$ 0.001
Common stock, shares issued														13,736,597	20,821,353	13,736,597
Common stock, shares outstanding														13,736,597	20,821,353	13,736,597
Preferred stock, shares outstanding														0	0	0
Gross proceeds proceeds from issuance initial public offering																$ 5,524
Reclassification of deferred offering costs to shareholders equity															614	872
Issuance of common shares upon conversion of convertible notes payable and accrued interest																$ 884
Issuance of common shares upon conversion of accounts payable, shares																514,940
Conversion of accounts payable to shareholders equity																$ 1,789
Payments of Financing Costs																390
Debt Instrument, Periodic Payment																0
Number of shares issued, value					$ 900											4,652
Aggregate fair value of the common stock														$ 500		500
Warrants exercisable description				will be exercisable six months from issuance and will expire five and a half years from the issuance date.
Net proceeds															3,602
Deferred offering costs														$ 1,377	1,091	1,377
Fair value of shares															$ 482	$ 218
2023 Equity Incentive Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock reserved for future issuance																		1,650,000
Shares available for grant														1,478,000	877,395	1,478,000
Restricted Stock Units (RSUs) [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares vested															144,707	68,341
Number of shares unvested															33,413
Number of shares granted															745,312	240,341
Number of shares vested															16,707
Stock compensation-related expense for fair value vesting of restricted common stock															$ 482
Fair value of unamortized compensation															813
Restricted Stock Units (RSUs) [Member] | 2023 Equity Incentive Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Fair value of shares	$ 875
Related Party [Member]
Subsidiary, Sale of Stock [Line Items]
Due to related parties								$ 4													$ 14
Officer [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued																666
Discounted price percentage																40.00%
Payments of Financing Costs																$ 3
Chief Financial Officer [Member]
Subsidiary, Sale of Stock [Line Items]
Conversion of accounts payable																$ 172
Conversion of shares																51,610
Conversion price per share percentage																83.00%
Fair value accounts payable														$ 206		$ 206
Financing cost																34
Amount owed														$ 0		0
Board of Directors Chairman [Member] | Restricted Stock Units (RSUs) [Member]
Subsidiary, Sale of Stock [Line Items]
Aggregate stock granted	667,940
Fair value of shares	$ 75
Aggregate restricted stock unit	57,252
Director [Member] | Restricted Stock Units (RSUs) [Member]
Subsidiary, Sale of Stock [Line Items]
Fair value of shares															$ 31	$ 43
Number of shares granted															20,120	30,000
Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued																1,550,000
Additional shares issued																1,664
Issuance of common shares upon conversion of convertible notes payable and accrued interest
Issuance of common shares upon conversion of convertible notes payable and accrued interest, shares																368,371
Issuance of common shares upon conversion of accounts payable, shares																514,940
Conversion of accounts payable to shareholders equity
Debt Conversion, Converted Instrument, Shares Issued																1,664
Debt Instrument, Convertible, Conversion Price														$ 4		$ 4
Number of shares issued, value																$ 2
Warrants to purchase stock			175,000							210,000	35,700	35,700
Common stock issued for cash upon exercise of the company's equity line of credit, shares															3,510,000
Net proceeds															$ 2,988
Deferred offering costs															614
Fair value of shares
Aggregate restricted stock unit															144,707	68,341
Common stock were issued under the cashless exercise															11,402
Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants outstanding, weighted average exercise price			$ 1.40					$ 4.80		$ 1.23	$ 0.46	$ 0.40
Purchase of warrants								108,500
Warrants outstanding, outstanding number of options, shares														278,188	4,281,038	278,188	150,000
Warrant expiration															4 years 3 days
Warrant shares outstanding, intrinsic value															$ 4
Pre-Funded Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants outstanding, weighted average exercise price				$ 0.001
Warrants exercised															2,500,000
Common Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants outstanding, weighted average exercise price				$ 1.40
Warrant One [Member]
Subsidiary, Sale of Stock [Line Items]
Share price								$ 2.46
Warrants outstanding, weighted average exercise price								$ 2.40
Warrants outstanding, outstanding number of options, shares								19,688
Expected term								2 years 6 months
Volatility								100.00%
Dividend rate								0.00%
Risk free interest rate								3.49%
Fair value of warrant														$ 29
Warrant expiration								5 years
Convertible Notes Payable [Member]
Subsidiary, Sale of Stock [Line Items]
Convertible notes payable																				$ 675
Notes payable, current								$ 792
Accrued and unpaid interest								$ 92
Issuance of common shares upon conversion of convertible notes payable and accrued interest															$ 884
Convertible Notes Payable [Member] | Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of common shares upon conversion of convertible notes payable and accrued interest, shares								368,371
Cedars-Sinai Medical Center [Member]
Subsidiary, Sale of Stock [Line Items]
Share price														$ 2.40		$ 2.40
Conversion of accounts payable																$ 750
Conversion of shares																312,500
Conversion price per share percentage																60.00%
Fair value accounts payable														$ 1,250		$ 1,250
Financing cost																$ 500
Another Cedars Sinai Medical Center [Member]
Subsidiary, Sale of Stock [Line Items]
Share price														$ 1.33		$ 1.33
Conversion of accounts payable																$ 200
Conversion of shares																150,830
Conversion price per share percentage																60.00%
Fair value accounts payable														$ 333		$ 333
Financing cost																133
Cross Current Capital LLC [Member] | Restricted Stock Units (RSUs) [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued						367,647
Number of shares issued, value						$ 500
Consulting Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued		367,647
Number of shares issued, value		$ 500				200
Aggregate fair value of the common stock														$ 500	$ 500	$ 500
Fair value of shares						$ 500
Aggregate restricted stock unit						367,647
Consulting Agreement [Member] | Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued		166,541
Number of shares issued, value		$ 157
Strategic Advisory Agreement [Member] | Restricted Stock Units (RSUs) [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued							50,000
Fair value of shares							$ 100
Number of shares vested															50,000	0
Number of shares unvested															0
Four Officers Agreement [Member] | Restricted Stock Units (RSUs) [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued													92,000
Fair value of shares													$ 226
Number of shares vested															78,000	0
Number of shares unvested															14,000
Security Purchase Agreement [Member] | Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock were issued under the cashless exercise															17,850
Purchase of warrants															17,850
IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued								1,550,000
Share price								$ 4.00
Gross proceeds proceeds from issuance initial public offering									$ 6,200
Net proceeds proceeds from issuance initial public offering								$ 5,524
Reclassification of deferred offering costs to shareholders equity															$ 872
Additional shares issued								232,500
IPO [Member] | Underwrinting Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued								108,500
Warrants outstanding, weighted average exercise price								$ 4.80
60% of IPO Closing Price [Member] | Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Debt Instrument, Convertible, Conversion Price														$ 2.40		$ 2.40
Security Purchase Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Purchase price of pre-funded unit			$ 3,500
Shares issued, price per share			$ 1.40
Net proceeds received from financing			$ 3,058
Security Purchase Agreement [Member] | Pre-Funded Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of stock, number of shares issued in transaction				2,500,000
Exercisable price per share				$ 0.001
Warrants to purchase stock				3,750,000
Security Purchase Agreement [Member] | Pre-Funded Warrant [Member] | Investor [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants outstanding, weighted average exercise price			$ 0.001
Warrants to purchase stock			2,500,000												2,500,000
Security Purchase Agreement [Member] | Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Exercisable price per share				$ 1.399
Security Purchase Agreement [Member] | Warrant [Member] | Investor [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants outstanding, weighted average exercise price															$ 1.40
Warrants to purchase stock															3,750,000
Warrants exercisable description															The warrant will be exercisable six months from the date of issuance (July 2025) and will expire five years from the issuance date.
Security Purchase Agreement [Member] | Warrant [Member] | Underwriters [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants exercisable description			The warrant expires five years from the date of grant.							The warrants expire five years from the date of grant.	The warrants expire five years from the date of grant.	The warrants expire five years from the date of grant.